Terlipressin and Albumin vs Albumin in Patients With Cirrhosis and Hepatorenal Syndrome: A Randomized Study
To access this article, please choose from the options below
Supported by grants from Fundació Marató TV3 (2000.TV.2710-0) and Ministerio de Educación y Ciencia (SAF 2001/0300) and Instituto Reina Sofia de Investigación Nefrologia; a grant from the Fundación Banco de Bilbao-Vizcaya-Argentaria (FBBVA; to M.M-L.); a grant from the Fondation du Centre Hospitalier de l'Université de Montréal (CHUM; to M-N.P.); and a grant from Fondo de Investigación Sanitaria (FIS 01/3045; to M.G.). Ciberehd is funded by the Instituto de Salud Carlos III.
Financial disclosures and conflicts of interest: Pere Ginès has received research support and lecture fees from Ferring Pharmaceuticals and research support from Orphan Therapeutics. Mónica Guevara has received lecture fees from Ferring Pharmaceuticals. The remaining authors have no conflicts of interest.
M.M-L. and M-N.P. contributed equally to this work.
PII: S0016-5085(08)00252-7
doi:10.1053/j.gastro.2008.02.024
© 2008 AGA Institute. Published by Elsevier Inc. All rights reserved.
Refers to article:
- Vasoconstrictor Therapy for the Hepatorenal Syndrome

